Boothbay Fund Management, LLC Corvus Pharmaceuticals, Inc. Transaction History

Boothbay Fund Management, LLC

  • $3.37 Billion
  • Q2 2024

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Aug 15, 2022
SELL
$0.87 - $2.03 $41,943 - $97,868
-48,211 Closed
0 $0
Q4 2021

Feb 14, 2022
SELL
$2.34 - $5.31 $64,263 - $145,828
-27,463 Reduced 36.29%
48,211 $116,000
Q3 2021

Nov 15, 2021
BUY
$1.89 - $8.53 $121,855 - $549,963
64,474 Added 575.66%
75,674 $366,000
Q1 2021

May 17, 2021
BUY
$2.86 - $4.77 $32,032 - $53,423
11,200 New
11,200 $34,000

Others Institutions Holding CRVS

# of Institutions
52
Shares Held
28M
Call Options Held
22.9K
Put Options Held
29.8K
View Full List

About Corvus Pharmaceuticals, Inc.

CRVS Quotes by TradingView
  • Ticker CRVS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 46,553,500
  • Market Cap $401M
  • Description
  • Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, which is in Phase Ib/II clinical trial for non-small cell lung cancer and head and neck cancers. The compan...
More about CRVS
Track This Portfolio

Track Boothbay Fund Management, LLC Portfolio

Follow Boothbay Fund Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Boothbay Fund Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Boothbay Fund Management, LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email